Alexander J. Kaplan

Alexander J. Kaplan

Auto-generated profile, based on publicly available information

Alexander J. Kaplan

Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2024 in Canadian Journal of Ophthalmology
Verified
Journal Article
Open access
JXJim S. Xie
Jim S. Xie
VOVanessa Ocampo
Vanessa Ocampo
AKAlexander J. Kaplan
Alexander J. Kaplan
Anterior uveitis presents a diagnostic challenge due to its wide array of etiologies and clinical manifestations. This narrative review aims to equip general ophthalmologists with a comprehensive understanding of anterior uveitis epidemiology, diagnosis, and treatment. Particular emphasis is placed on developing a tailored and stepwise strategy, rather than a one-size-fits-all approach, for the workup and treatment of anterior uveitis. Chest radiography and serologic testing for syphilis, human leukocyte antigen B27, and angiotensin-converting enzyme are appropriate routine investigations in cases of severe, bilateral, recurrent, or chronic anterior uveitis. Additional testing should be guided by clinical findings and regional epidemiology, especially when considering expensive and invasive modalities. Investigations that are obtained in the absence of clinical and epidemiologic orientation are of limited utility and incur significant costs to patients and health care systems. Most cases of anatomically isolated anterior uveitis resolve with topical corticosteroids, but some patients require escalation to systemic immunomodulatory therapy (IMT). IMT should be considered in patients who respond poorly to corticosteroids, develop side effects related to corticosteroids that limit their use, require high doses to maintain disease remission, or have concomitant systemic inflammatory disease. Comprehensive ophthalmologists should feel comfortable comanaging patients that require conventional disease-modifying antirheumatic drugs/antimetabolite therapy (i.e., methotrexate, azathioprine, and mycophenolate mofetil) with rheumatologists and providing guidance on ocular dosing. When uveitis quiescence cannot be achieved despite maximally tolerated antimetabolite therapy, patients should be referred to a uveitis specialist for consultation and consideration of IMT escalation. The timing of uveitis referral may depend on local factors specific to health care jurisdictions.

10 April 2022 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
FMFahmeeda Murtaza
Fahmeeda Murtaza
APAustin Pereira
Austin Pereira
MMMark S. Mandelcorn
Mark S. Mandelcorn
AKAlexander J. Kaplan
Alexander J. Kaplan
To report a case of Vogt–Koyanagi–Harada (VKH) disease following influenza vaccination. A 30-year-old Filipino male developed bilateral pain, redness, photophobia, floaters, headache and tinnitus 2 days after receiving the annual influenza vaccine. He presented to the emergency department 5 days after symptom onset. His past medical and ocular history was unremarkable. His best-corrected distance visual acuity (BCVA) was 20/100 in the right eye (OD) and 20/150 in the left eye (OS). Slit-lamp examination revealed fine keratic precipitates and 1+ anterior chamber cells in both eyes (OU). Dilated fundus examination revealed 1+ vitreous cells with trace haze and multiple serous retinal detachments OU. Magnetic resonance imaging (MRI) of the brain and chest X-ray were unremarkable. Serologic testing was negative for infectious, inflammatory and neoplastic causes. The patient tested positive for HLA-DR4. A diagnosis of acute Vogt-Koyanagi-Harada disease was made and high-dose oral prednisone, intravitreal triamcinolone acetonide and mycophenolate mofetil were needed to achieve quiescence. At 6 months follow-up, our patient remains in remission with no active intraocular inflammation or subretinal fluid. His BCVA has improved to 20/50 OD and 20/30 OS. The annual influenza vaccine may be a trigger for onset or recurrence of VKH in genetically susceptible individuals.

30 April 2022 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
APAustin Pereira
Austin Pereira
FMFahmeeda Murtaza
Fahmeeda Murtaza
AKAlexander J. Kaplan
Alexander J. Kaplan
PYPeng Yan
Peng Yan
To describe an atypical ocular manifestation following SARS-CoV-2 infection. A 27-year old previously healthy male with no past ocular history presented with pain, photophobia and red eye in his left eye (OS). His only notable mention on review of systems was a positive SARS-CoV-2 infection three weeks prior. Slit lamp examination demonstrated fine inferior keratic precipitates (KPs) in the inferior cornea and 3+ anterior chamber cells OS. There was no vitritis or chorioretinal lesions. The patient was diagnosed with his first event of acute anterior uveitis. Standard ocular inflammatory panel returned positive for HLA-B27. The postulated mechanism of initial anterior uveitis attack in the setting of COVID-19 infection was dysregulation of inflammatory cells and mediators in a patient with baseline elevated risk for ocular inflammation. It is crucial to investigate patients for HLA-B27 following initial anterior uveitis event if infected by SARS-CoV-2, as patients with HLA-B27 are at baseline higher risk of ocular inflammatory dysregulation.

17 December 2023 in Canadian Medical Association Journal
Verified
Journal Article
Open access
PDF file
JXJim S. Xie
Jim S. Xie
AKAlexander J. Kaplan
Alexander J. Kaplan
A 58-year-old, bisphosphonate-naive woman with a history of Hashimoto thyroiditis was admitted to hospital for hypercalcemia (2.81 [normal 2.20-2.60] mmol/L) due to primary hyperparathyroidism. She received 60 mg of intravenous pamidronate. Two days later, she developed right eye pain, photophobia and blurred vision, with progressive redness and periorbital swelling. She presented to an emergency eye clinic 6 days later and had a visual acuity of 20/30 in the left eye and only light perception in the right eye, with proptosis, an adduction deficit, corneal edema and a hypopyon (Figure 1A). The posterior segment view was obstructed but no vitritis was seen on B-scan ultrasonography. Computed tomography of the orbits revealed right-sided diffuse scleral thickening (Figure 1B). She was treated empirically with topical moxifloxacin, corticosteroids and cycloplegics. Infectious and inflammatory work-up was negative, apart from an elevated C-reactive protein (16.4 [normal < 3] mg/L). We saw the patient a week later and diagnosed drug-induced anterior uveitis with scleritis from the pamidronate infusion. Her intraocular inflammation resolved after starting oral corticosteroids with a slow taper. At the 7-week follow-up visit, her visual acuity in the right eye had improved to 20/50. The patient eventually received a parathyroidectomy, which resolved her hypercalcemia. The differential diagnosis of anterior uveitis with scleritis includes infectious, autoimmune, traumatic, neoplastic and druginduced causes. For this patient, neoplasm was ruled out as she had no posterior segment involvement. Infectious and autoimmune disorders were considered and empirically treated pending investigations, which later returned as negative. Drug-induced uveitis or scleritis may be seen with use of parenteral or oral bisphosphonates, with incidence rates of 7-114 per 10 000 and 8-63 per 10 000 people per year, respectively. 1,2 Onset of uveitis or scleritis tends to be faster after parenteral (1-7 d) than oral (days to months) bisphosphonates. 2 If patients develop red eye associated with pain, photophobia, blurred vision, or periorbital swelling within a week of new medication exposure, the medication should be stopped immediately. Suspected drug-induced uveitis is managed empirically with topical corticosteroids and antibiotics with close follow-up by an ophthalmologist.

29 February 2024 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
Tina FelfeliTina Felfeli
Tina Felfeli
JRJess Rhee
Jess Rhee
AEArshia Eshtiaghi
Arshia Eshtiaghi
Michael BalasMichael Balas
Michael Balas
FTFelicia Tai
Felicia Tai
LDLarissa A. Derzko-Dzulynsky
Larissa A. Derzko-Dzulynsky

24 March 2024 in Canadian Medical Association Journal
Verified
Journal Article
Open access
PDF file
JXJim S. Xie
Jim S. Xie
AKAlexander J. Kaplan
Alexander J. Kaplan